Summary
Vertex Pharmaceuticals Incorporated (VRTX) filed an 8-K on January 12, 2004, to disclose information regarding its 2003 accomplishments and its financial outlook for 2004. The report primarily references a press release issued on January 12, 2004, which contains the detailed information. Investors should note that this filing itself does not contain extensive financial data but serves as a notification that a press release with results and guidance has been disseminated.
Key Highlights
- 1Vertex Pharmaceuticals issued an 8-K filing on January 12, 2004.
- 2The filing's primary purpose is to report on 2003 accomplishments.
- 3The press release attached (Exhibit 99.1) reiterates Vertex's full-year 2003 financial guidance.
- 4The press release also provides Vertex's outlook for 2004.
- 5The information provided in this 8-K is not considered 'filed' for the purposes of Section 18 of the Exchange Act.
- 6The filing serves as a reference point for investors to access the detailed press release for financial performance and future guidance.
Frequently Asked Questions
The main purpose of this 8-K filing is to formally notify the SEC and investors that Vertex Pharmaceuticals has issued a press release containing its 2003 accomplishments, a reiteration of its full-year 2003 financial guidance, and its 2004 outlook.
The detailed financial results and 2004 outlook are contained within the press release that is attached to this 8-K filing as Exhibit 99.1.
No, the information in this 8-K filing is explicitly stated as not being deemed 'filed' for the purposes of Section 18 of the Securities Exchange Act of 1934 or subject to the liabilities of that section, unless specifically incorporated by reference in a future filing.
The filing states that the press release reiterates Vertex's full-year 2003 financial guidance. Specific figures would be found in the attached press release (Exhibit 99.1).